8-K: Co-Diagnostics Reports Q1 2026 Results, Focus on Global Expansion

Co-Diagnostics announced its first quarter 2026 financial results, highlighting regulatory progress in India, expanded distribution in South Asia, and continued investment in R&D.

Summary

• Co-Diagnostics reported Q1 2026 revenue of $0.15 million, an increase from $0.05 million in Q1 2025.
• Operating expenses rose to $9.2 million from $8.6 million year-over-year, primarily due to R&D spending.
• The company reported an operating loss of $9.2 million and a net loss of $9.1 million ($4.06 per share) for the quarter.
• Adjusted EBITDA loss was $8.7 million, compared to $7.4 million in the prior year's quarter.
• Cash and cash equivalents decreased to $8.2 million from $11.9 million at the end of 2025.
• Key business developments include receiving a CDSCO license for CoSara PCR Pro in India and expanding CoSara Diagnostics' territory to include Bangladesh, Pakistan, Nepal, and Sri Lanka.
• The company is preparing for a 510(k) FDA filing for its upper respiratory multiplex test and initiating TB clinical performance studies in India.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to increased operating losses and reduced cash reserves, despite some positive regulatory and market expansion milestones.

Positives

• Revenue increased to $0.15 million in Q1 2026 from $0.05 million in Q1 2025.
• Received CDSCO license to manufacture and sell the CoSara PCR Pro instrument in India.
• Achieved ISO 13485 certification for CoSara's manufacturing facility in India.
• Expanded CoSara Diagnostics' commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal, and Sri Lanka, increasing the regional addressable market to approximately $13 billion.
• Initiated shipments of PCR Pro instruments and TB test materials to India.
• Strengthened distributor relationships and expanded market presence through regional conferences.
• Expanded intellectual property portfolio with a new international patent in Japan.
• Completed enrollment in upper respiratory Co-Dx test clinical studies with over 1,400 patients.

Negatives

• Operating expenses increased to $9.2 million from $8.6 million year-over-year.
• Operating loss widened to $9.2 million from $8.6 million in the prior year's quarter.
• Net loss increased to $9.1 million ($4.06 per share) from $7.5 million ($7.05 per share) in Q1 2025.
• Adjusted EBITDA loss increased to $8.7 million from $7.4 million in Q1 2025.
• Cash and cash equivalents decreased to $8.2 million from $11.9 million at the end of 2025, indicating ongoing cash burn.
• Gross profit was a loss of $47,814 in Q1 2026, compared to a gross profit of $28,687 in Q1 2025.

Risks

• The Co-Dx PCR platform, including PCR Home and PCR Pro, is subject to review by the FDA and other regulatory bodies and is not yet available for sale.
• Actual results may differ materially from forward-looking statements due to inherent uncertainties, risks, and changes in circumstances.
• There can be no assurance that any regulatory submission, authorization, commercialization milestone, manufacturing initiative, strategic collaboration, or market opportunity will occur on the anticipated timelines, or at all.
• The company faces risks and uncertainties as discussed in its Annual Report on Form 10-K filed March 31, 2026, and other SEC filings.

Future Outlook

The company expects continued investment in clinical development, regulatory, and commercialization activities as it advances its strategic initiatives. Management believes it has generated data to support a regulatory submission for its upper respiratory multiplex test with the FDA and is preparing to initiate clinical performance studies for its MTB program in India.

Management Comments

• "The progress weve made across the business is translating into tangible milestones and expanded opportunities," said Dwight Egan, Chief Executive Officer of Co-Diagnostics.
• "During the quarter, we advanced key initiatives across our clinical pipeline, strengthened our presence in strategic global markets through CoSara and CoMira, and continued to build the foundation for a scalable, globally deployable diagnostics platform."
• "These efforts reflect a focused strategy centered on execution, innovation, and expanding our reach into high-need markets."
• "We believe we have generated the data needed to support a regulatory submission for our upper respiratory multiplex test and are advancing toward a 510(k) filing with the FDA."
• "We are also preparing to initiate clinical performance studies for our MTB program in India, which we believe represents one of the most significant near-term opportunities for the platform."
• "Together with continued progress across our international initiatives, these developments demonstrate continued operational progress against our strategy and that we are entering the next phase of execution with increasing momentum and a clearer path toward commercialization."

Industry Context

StockSavvy.ai notes that Co-Diagnostics' Q1 2026 results reflect the challenging but opportunity-rich landscape of the molecular diagnostics sector, particularly in emerging markets. The company's focus on regulatory approvals (India) and market expansion (South Asia) aligns with global health trends prioritizing accessible and advanced diagnostic solutions, especially for infectious diseases like TB.

Stakeholder Impact

• Shareholders: Continued investment in R&D and expansion may lead to future growth but also entails ongoing financial risk due to current losses and cash burn.
• Employees: Increased R&D spending may support job growth and innovation within the company.
• Customers: Expansion into new South Asian markets and progress on regulatory approvals could lead to increased availability of diagnostic tools.
• Suppliers: Increased manufacturing and R&D activities may lead to higher demand for supplies and services.

Next Steps

• Advance toward a 510(k) filing with the FDA for the upper respiratory multiplex test.
• Initiate clinical performance studies for the MTB program in India.
• Continue commercialization and manufacturing activities involving CoSara and CoMira.
• Pursue international expansion initiatives and partnerships.

Key Dates

Recommendation

The company shows progress in international expansion and regulatory milestones, which are positive long-term indicators. However, the increasing operating losses, widening net loss, and significant decrease in cash reserves present considerable short-term financial risks. The path to profitability remains uncertain, warranting a 'hold' recommendation until clearer signs of revenue growth translating into improved financial performance emerge.

Keywords

Co-Diagnostics, Molecular Diagnostics, PCR Platform, CoSara Diagnostics, Financial Results, Q1 2026, Regulatory Approval, India